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Abstract
Introduction: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes
(CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available
on the optimal schedule of administration of this drug. The aim of the present study was to analyse the impact of
canakinumab on CAPS patients in daily clinical practice and to identify the best schedule of administration
according to age and phenotype.
Methods: 13 CAPS patients (10 children and 3 young adults) treated with canakinumab were followed for 12
months. Clinical and laboratory parameters were collected at each visit. Health-related quality of life (HRQoL) was
recorded at month 12. Complete response was defined as absence of clinical manifestations and normal
examinations. Clinical and laboratory variables at last follow-up were compared with those registered at the
moment of anakinra discontinuation.
Results: seven patients with chronic infantile neurological cutaneous articular (CINCA) syndrome, four patients with
Muckle-Wells syndrome (MWS) and two patients with an overlapping MWS/CINCA phenotype were analysed.
CINCA patients experienced a higher number of modifications of the treatment (increased dosage or decreased
dosing interval) in respect to MWS patients. At the end of the follow-up CINCA patients displayed a higher
frequency of administration with a median dose of 3.7 mg/kg (2.1 mg/kg for MWS patients). Canakinumab was
withdrawn in a patient with CINCA for incomplete response and poor compliance. The effect of canakinumab on
HRQoL was similar to that observed during treatment with anakinra, with the exception of an improvement of the
psychosocial concepts after the introduction of canakinumab.
Conclusions: The use of canakinumab in daily practice is associated with persistent satisfactory control of disease
activity but needs progressive dose adjustments in more severe patients. The clinical phenotype, rather than the age,
represents the main variable able to determine the need of more frequent administrations of the drug at higher dosage.
Introduction
Familial cold autoinflammatory syndrome (FCAS),
Muckle-Wells syndrome (MWS) and chronic infantile
neurological cutaneous and articular syndrome (CINCA)
represent the clinical spectrum associated to mutations
in NLRP3 gene coding for the cryopyrin protein [1,2]
and are collectively known as cryopyrin-associated peri-
odic syndrome (CAPS).
FCAS is characterized by urticarial rash, arthralgia and
fever spikes of short duration induced by cold exposure
[3]. In MWS recurrent episodes of urticaria-like erup-
tions, fever, chills, malaise and limb pain occur from
childhood onwards and are associated with the late devel-
opment of sensorineural hearing loss and amyloidosis [4].
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CINCA (or neonatal onset multi-systemic inflammatory
disease, NOMID) represents the most severe condition
and is characterized by a neonatal onset urticarial-like
rash, fever, central nervous system (CNS) involvement
(mental retardation, chronic aseptic meningitis, increased
intracranial pressure, cerebral atrophy, ventriculomegaly,
sensorineural hearing loss and chronic papilledema),
chronic inflammatory arthropathy, skeletal dysplasia and
specific facial and dysmorphic features [5].
Cryopyrin is involved in the assembly of an intracellu-
lar multi-protein complex (called inflammasome) that
plays a pivotal role in the induction and secretion of the
biologically active 17 kD form of IL-1b [6,7]. Anti-IL-1
blockers are highly effective in CAPS. The short- [8-10]
and long-term [11-13] effectiveness of the IL-1 receptor
antagonist (anakinra) in CAPS have been already
described in the last few years. Other IL-1 inhibitors,
such as rilonacept, a human dimeric fusion protein that
incorporates the extra-cellular domain of both IL-1
receptor type I and IL-1 receptor accessory protein [14],
and a fully human anti-IL-1b monoclonal antibody,
canakinumab are also available [15].
In a recent trial the use of subcutaneous doses of 150
mg (or 2 mg/kg) of canakinumab every 8 weeks for 24
weeks was generally associated with complete control of
clinical manifestations and laboratory parameters in
patients with a prevalent MWS phenotype [15]. These
positive results were confirmed in the following 24-
month phase III trial [16]. Interestingly, in this latter
study a relevant percentage of patients required modifi-
cation of the treatment schedule by means of increased
dosage and/or frequency of administration [16]. This
was mainly observed in pediatric and CINCA patients
who were not included in the previous trial. However,
the description of the pattern of disease activity and the
strategy used for the modified treatment schedule were
not reported [16].
In this retrospective multicenter study we describe one
year of follow-up in a cohort of pediatric and CAPS
patients treated with canakinumab. The main aims were
to 1) verify the efficacy and safety of the drug in every-
day clinical practice, 2) evaluate the impact of the drug
on the quality of life, and 3) identify the best schedule
for CAPS patients according to their age and phenotype.
Materials and methods
Thirteen unrelated CAPS patients (female:male ratio 7:6;
10 children, 3 adults; mean age 14.6 years, range 8.7 to
38 years) were enrolled in the study from five pediatric
rheumatology centers. Twelve of these patients were
previously enrolled in the CACZ885D2306 trial [16].
According to their phenotype, seven patients were clas-
sified with CINCA for the presence of early-onset urti-
carial skin rash associated with involvement of the CNS
(papilledema, early-onset hearing loss, brain atrophy at
MRI, severe headache) and bone dysplasia [2,17]. Four
patients were classified with MWS syndrome (absence
of CNS involvement and bone dysplasia). Two patients
were defined as having an overlapping phenotype
between MWS and CINCA for the presence of early-
onset hearing loss and/or papilledema in the absence of
brain atrophy, mental retardation or bone dysplasia. Ten
patients carried mutations in the NLRP3 gene (Table 1).
At the end of the CACZ885D2306 study (July 2010),
all patients continued treatment with canakinumab in
an open fashion with the last schedule (dose and fre-
quency) used during the trial. Before the registration of
the drug in Italy (November 2010), patients received the
treatment for compassionate use, provided by Novartis,
Italy. An additional patient was treated soon after the
registration of the drug. The study was approved by the
Ethical Board of the G. Gaslini Institute. Local ethical
boards also approved the study in each center. Informed
consent was obtained from patients or families. Patients
were followed at their center with monthly or bi-
monthly visits. According to normal daily clinical prac-
tice used in Italian centers for patients with CAPS the
following parameters were recorded: 1) presence of dis-
ease-associated manifestations (skin rash, arthralgia/
arthritis, myalgia, headache and conjunctivitis) and the
global evaluation of disease activity with a four-point
scale as absent (0), minimal (1), moderate (2), severe (3)
[16]; 2) laboratory parameters, including hemogram, C-
reactive protein (CRP), serum amyloid A protein (SAA);
3) eye examination and audiogram (with a frequency of
3 to 6 months according the policy at each center), and
4) a national language version of the parent-adminis-
tered 50-item version of the Child Health Questionnaire
(CHQ-PF 50) at month 12, as previously described [11].
Modifications of dose and/or frequency of administra-
tion of canakinumab were performed according to the
judgment of the physician in charge based on the clini-
cal picture and/or laboratory parameters. Adverse events
were also registered. After 12 months of treatment, data
from clinical charts were retrospectively evaluated.
Response to treatment was evaluated as follows: i) com-
plete response: absent or minimal disease activity at the
global assessment with acute phase reactants within the
normal range, ii) partial response: absent or minimal
global disease activity associated with elevation of acute
phase reactants, or iii) inadequate response: moderate or
severe global disease activity associated with elevated
acute phase reactants.
Intra-individual comparison between anakinra and
canakinumab
Twelve out of thirteen patients were previously treated
with anakinra for a median period of 42 months (range
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12 to 60 months) [11]. For these patients, clinical and
laboratory variables at the time of anakinra withdrawal
were retrospectively evaluated. The CHQ-PF 50 admi-
nistered after 12 months of treatment with canakinumab
was compared with the same evaluation performed in
the same patients during anakinra treatment [11], using
the non-parametric Wilcoxon pairs test.
Results
Baseline
At the end of the ACZ885D2306 trial seven patients
(three with MWS, one with MWS/CINCA and three
with CINCA) were treated at the dose of 2 mg/kg (or
150 mg if body weight was > 40 Kg) every 8 weeks,
which was the starting dose used in the trial [16]. Due
to incomplete control of disease activity, five patients
(one with MWS/CINCA and four with CINCA) experi-
enced increasing dosing during the trial and were there-
fore receiving 4 mg/kg (or 300 mg, if body weight was >
40 Kg) every 8 weeks (Table 1). The MWS patient
(number 13) who was treated after the registration of
the drug received the starting dose of 2 mg/kg every 8
weeks according to the terms of the marketing
authorization.
At baseline four patients with the MWS or MWS/
CINCA phenotype (patients number 5, 9, 10 and 13)
were in complete remission, while two of them (patients
6 and 8) were in partial remission (Table 1). Among
patients with CINCA, a complete or partial response
was observed in one (patient 12) and five (patients 1, 3,
4, 7 and 11), respectively (Table 1). One patient
(number 2) was considered a non-responder due to the
presence of both clinical manifestations and elevation of
acute phase reactants.
Follow-up period
In Figure 1 the clinical and laboratory variables during
the 12 months of follow-up in patients with less severe
(MWS and MWS/CINCA, panel A) and more severe
(CINCA, panel B) phenotypes are shown. Of the six
patients with the MWS and MWS/CINCA phenotypes,
three (patients 5, 9, and 10) did not require any adjust-
ment of the therapy due to a persistent optimal control
of both clinical and laboratory parameters during the
whole follow-up period (Figure 1A). Two others
(patients 6 and 8) required at least one modification of
the treatment schedule due to a persistent elevation of
acute phase reactants (Figure 1A). After three doses,
due to the persistent control of clinical and laboratory
parameters, the dosing frequency for patient number 13
was decreased to every 10 weeks. At the following visit,
in the light of persistent and complete wellbeing, both
the physician and the parents of the patient agreed to
discontinue the treatment with the aim of using the
drug only on demand. At the end of follow-up the
majority of MWS and MWS/CINCA patients were trea-
ted with a dose below 2.5 mg/kg. Only patient number
6, presenting a MWS/CINCA phenotype with a T348M
mutation, required a higher dose (3.7 mg/kg) due to
persistent elevation of acute phase reactants (Table 2).
Six out of seven patients with CINCA received at least
one modification of the canakinumab schedule. Due to a
Table 1 Demographic data, duration of treatment, schedule (dose and frequency) of canakinumab and response to






















1 CINCA N477K birth 5 65 4.6 300 8 partial
2 CINCA F573S birth 5 38 4.0 152 8 inadequate
3 CINCA Negative 2 months 5 50 6.0 300 8 partial





1 week 12 29 2.0 72 8 complete
6 MWS/
CINCA
T348M 6 months 11 85 3.5 300 8 partial
7 CINCA E304K birth 12 78 3.8 300 8 partial
8 MWS T348M birth 12 63 2.4 150 8 partial
9 MWS E525K 15
months
17 62 2.4 150 8 complete
10 MWS D303N 3 weeks 20 37 2.0 74 8 complete
11 CINCA T348M birth 15 23 2.0 46 8 partial
12 CINCA Negative birth 7 61 2.5 150 8 complete
13 MWS V198M 9 years - 38 2.0 76 8 complete
CINCA: chronic infantile neurological cutaneous articular syndrome; MWS: Muckle-Wells syndrome; MWS/CINCA: overlap syndrome.
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Figure 1 C-reactive (CRP) in mg/dl, serum amyloid A (SAA) in mg/l and global physician assessment during 12 months of follow-up in
patients with Muckle-Wells Syndrome (MWS) and overlapping MWS/chronic infantile neurological cutaneous and articular syndrome
(CINCA). Panel A: patients with MWS and overlapping MWS/CINCA; panel B: patients with CINCA. Arrows represent changes in the treatment
schedule (dose or frequency). Pt, patient.
Table 2 Dose of anti-IL drug, acute phase reactants, physician assessment of disease and response to treatment at last
follow-up on treatment with Canakinumab and at the moment of anakinra withdrawal




















11 300 (4.30)/5 wks 1.17 29.9 mild partial 75 (1.30)/day 0.61 25.0 absent partial
21 150 (4.00)/6 wks 1.18 ND moderate inadequate 75 (2.00)/day neg 18.0 absent partial
31 300 (5.90)/6 wks 2.67 18.1 absent partial 100 (1.80)/day 0.47 7.50 absent partial
41 150 (2.80)/6 wks neg neg absent complete 100 (2.00)/day neg neg minimal complete
52 78 (2.00)/8 wks neg neg absent complete 55 (2.00)/day neg neg minimal complete
62 300 (3.75)/7 wks 0.57 6.5 absent partial 100 (1.16)/day 0.63 neg mild partial
71 300 (3.70)/4 wks 1.20 64.0 mild partial 100 (1.30)/day 0.73 neg absent partial
82 150 (2.30)/6 wks neg neg absent complete ND ND ND ND ND
92 150 (2.40)/8 wks neg neg absent complete 50 (1.00)/day neg neg absent complete
102 100 (2.00)/8 wks neg neg absent complete 20 (0.66)/day neg neg absent complete
111 60 (2.00)/7 wks neg neg absent complete 23 (1.00)/day neg 13.2 mild partial
121 150 (2.00)/8 wks neg neg absent complete 55 (1.00)/day neg neg absent complete
132 78 (2.00)/10 wks neg neg absent complete 38 (1.00)/day neg neg absent complete
1Patients with the chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2patients with the Muckle-Wells syndrome (MWS) and
MWS/CINCA phenotype; CRP, C reactive protein; SAA, serum amyloid A; neg, negative; ND, not done.
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persistent elevation of acute phase reactants associated
with mild clinical manifestations, patients 3, 4 and 11
required a single modification of the frequency. In
patients 1 and 7 the frequency was increased three and
two times to a final schedule of 300 mg every 5 and 4
weeks, respectively (Table 2). Patient 2 was treated at
baseline with 300 mg every 8 weeks. The frequency of
administration of canakinumab was initially increased to
every 6 weeks because of the persistence of disease
activity (Figure 1B). At the following evaluation both the
physician in charge and parents preferred to discontinue
canakinumab due to the persistence of disease-asso-
ciated symptoms (arthralgia and malaise), the presence
of possible side effects (dizziness) and the remarkable
elevation of acute phase reactants (Figure 1B). The
patient was subsequently treated with anakinra, (2 mg/
kg/day) with a complete control of the clinical manifes-
tations and normalization of acute phase reactants.
The comparison between the two subgroups (MWS and
MWS/CINCA vs CINCA) did not reveal any difference in
their median age (Table 3). Conversely, during the course
of the study CINCA patients experienced a higher num-
ber of adjustments (increased dose or decreased dosing
interval) in respect to MWS patients (Table 3). At the end
of the follow-up CINCA patients had required a higher
frequency of administration and a trend towards the need
for a higher median dose (3.7 vs 2.1 mg/kg) (Table 3).
During the 12 months of follow-up repeated audio-
grams and eye examinations did not show substantial
changes from baseline. Flares of headache, or modifica-
tions in behavior or mental performance were not
observed. Compliance with treatment was good, and no
reactions at the site of the injection were recorded.
Patient number 8 presented with cellulitis of the leg at
month 11, which required hospitalization for intravenous
antibiotic treatment. Methicillin-resistant staphylococcus
aureus was isolated. The administration of canakinumab
was postponed until the complete resolution of the infec-
tion, which occurred without complications.
The 15 subscales of the CHQ and the two summary
scores, the physical summary score (PhS) and the psy-
chosocial summary score (PsS), recorded at the time of
the last follow-up and the reference values for healthy
controls are reported in Figure 2. Overall, the health-
related quality of life (HRQoL) of canakinumab-treated
CAPS patients was generally comparable to that
recorded in the control group. Patients with CAPS still
presented a significantly impaired perception of general
health (P < 0.001) and physical functioning (P = 0.02)
when compared with healthy controls.
Within-patient comparison of anakinra and canakinumab
Twelve out the thirteen patients treated with canakinu-
mab were previously treated with anakinra. We therefore
evaluated for each patient whether the pattern of
response to canakinumab was different from that regis-
tered at the time of anakinra withdrawal. At the time of
the last administration of anakinra six patients (two with
CINCA, one with MWS/CINCA and three with MWS)
displayed a complete response (Table 2). Six patients (five
with CINCA, one with MWS/CINCA) displayed a partial
response due to a slight increase of acute phase reactants
(Table 2). All five patients presenting a partial response
to canakinumab already showed a partial or inadequate
response to anakinra (Table 2).
We also had the possibility of comparing HRQoL at
the last follow-up of treatment with canakinumab to
that obtained at the time of anakinra withdrawal (Figure
2) [11]. The comparison did not reveal a significant dif-
ference of the impact of the two drugs on physical con-
cepts. Conversely, canakinumab treatment was
associated with a significant amelioration of psychosocial
concepts (P = 0.03), especially for the parental emo-
tional perception of the disease (P = 0.045) with a trend
towards significance for self-esteem (P = 0.09) and par-
ental time (P = 0.1) (not shown).
Discussion
In the present paper we describe the impact of canaki-
numab in the daily clinical practice in a cohort of CAPS
patients mostly characterized by pediatric age and/or a
severe phenotype. After one year of follow-up, twelve
out of thirteen patients displayed complete control of
clinical manifestations, with a slight elevation of acute
Table 3 Comparison of age, duration of disease, final dose, frequency of administration of canakinumab and number






Age, years, median (range) 13.6 (10.7, 23.7) 15 (8.7, 38.0) 0.56*
Disease duration, median, years (range) 13,6 (3.0, 23.2) 15 (8.7, 38.0) 0.61*
Dose, mg/kg, median (range) 2.15 (2.0, 3.7) 3.7 (2.0, 5.9) 0.16*
Frequency, weeks, median (range) 8 (6, 10) 6 (4, 8) 0.03
Adjustments/year, number 2 9 0.05
1Includes two patients with a Muckle-Wells syndrome (MWS)/chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2Mann-Whitney
U-test, *not significant.
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phase reactants in four of them. In relation to the recent
report of Kummerle et al. [16] the present study ana-
lyzes in more detail the actual impact of canakinmab on
disease activity according to the disease phenotype.
Globally, patients with a mild-intermediate MWS phe-
notype display complete control of disease activity main-
taining the initial dosage of 2 mg/kg (or 150 mg) every 8
weeks, independent of their age. The majority of our
CINCA patients required an increase in the dose to 4
mg/kg (or 300 mg) during the ACZ885D2306 trial. For
most of them this dose adjustment was not sufficient to
achieve complete control of disease activity, and a pro-
gressive increase of the dosing frequency was needed in
the following 12 months. In the majority of the patients
the main reason for interval adjustment was the pre-
sence of a persistent elevation of acute phase reactants,
despite complete control of the clinical manifestations.
In one patient with severe CINCA (patient number 2),
the clinical manifestations persisted along with the ele-
vation of acute phase reactants, despite the previous
increase of the dose to 300 mg every 6 weeks. In this
case parents did not allow further increase in the fre-
quency of the administration or escalation of the dose
and asked for a return to the anakinra regimen.
The variability in the response to IL-1 blockers has
been already observed in previous studies. The wide use
of anakinra in all CAPS phenotypes has already provided
evidence that patients with CINCA generally need
higher doses to completely control disease activity com-
pared to patients with a milder CAPS phenotype
[11-13]. This is due to different reasons: first, the impact
of different NLRP3 mutations on the levels of secretion
of IL-1b from monocytes is variable, with higher levels
detected in the severe CINCA phenotype [7,18]. Second,
this phenotype is characterized by the inflammatory
involvement of the CNS and inner ear. In non-human
primates, the diffusion of anakinra in the CNS is pro-
portional to the systemic dose [19], supporting the need
for an increasing dose to achieve complete control of
CNS manifestations [13]. Third, most of the patients
with CINCA are treated during childhood. Even if there
are no clear data on the pharmacokinetic of IL-1 block-
ers in humans so far, it is conceivable that the bioavail-
ability of these drugs in children is lower than in adults.
Interestingly in our study, all patients who did not
achieve complete control of acute phase reactants at the
last follow-up of treatment with canakinumab, displayed
the same pattern at the moment of the anakinra with-
drawal, supporting the need to identify the proper dose
of IL-1 blockers on an individual basis. This issue might
be due to the different impact of the NLRP3 mutations
on disease severity. This seems to be the case for the
T348M mutation that in our experience determined an
increased dosage regimen independently from our classi-
fication according to the disease phenotype. On the
other hand the need to change the treatment schedule
was also observed in CINCA patients who were negative
for germ-line NLRP3 mutations.
In any case, all partial responders displayed a CINCA
phenotype, or had high body weight. In this line, the
Figure 2 Impact of different IL-1 blockers on health-related quality of life in patients with cryopyrin associated periodic syndromes
(CAPS) evaluated by the Child Health Questionnaire (CHQ-PF 50). Squared boxes represent the mean values obtained from the patients
before any treatment with IL-1 blockers (see also [11]). Triangles and circle boxes represent the mean values at the last follow-up with anakinra
and canakinumab treatment, respectively. *P < 0.05 (Wilcoxon pairs test). PhS: physical summary score. PsS: psychosocial summary score.
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existence of a single formulation for both anakinra (100
mg) and canakinumab (150 mg) represents a clear lim-
itation for the proper management of the more severely
affected patients.
In the present study we also compared the response to
treatment in CAPS patients after 12 months of canaki-
numab treatment with those registered at the moment
of anakinra withdrawal. This analysis has a number of
limitations related to the retrospective collection of data
and to the temporal gap (mean 23 months, range 18 to
36) between the last administration of anakinra and the
evaluation of the patients after 12 months of treatment
with canakinumab. Despite these limitations, our preli-
minary observations support the clinical perception of
substantial equivalence of the two IL-1 blockers in the
control of disease manifestations and their role in pro-
viding a sustained improvement in HRQoL [20]. With
no doubt, the possibility of avoiding daily injections
represented the main reason for observed better perfor-
mance according to scores for the psychological items,
when patients are treated with canakinumab. Due to its
higher molecular weight, canakinumab has a much
lower probability of reaching the CNS compared to ana-
kinra. Despite the theoretical concern about the minor
efficacy of canakinumab for CNS manifestations, none
of the CINCA patients enrolled in the study had evi-
dence of deterioration in CNS involvement during cana-
kinumab treatment. However, in the long run further
follow-up in larger series is needed to clarify this rele-
vant issue.
So far, the safety profile reported for anakinra in the
long run is rather good [11-13]. In our recent experi-
ence local erythematosus skin reaction at the injection
site (28.5% of treated patients), excessive weight gain
(14.2%) and severe oral aphthosis (7.1%) were the most
relevant reported adverse events [11]. In this study cana-
kinumab confirmed optimal tolerability together with a
good safety profile [15,16]. Infections should be carefully
and promptly recognized for proper and aggressive
treatment. In the case of infectious cellulitis the previous
use of canakinumab did not interfere with the time of
resolution of this complication. To our knowledge this
clinical manifestation has never been described in asso-
ciation with CAPS, or as a possible adverse event during
treatment with biologic agents.
Our study shows that the CAPS phenotype, rather
than patient age, represents the main variable to deter-
mine the need of more frequent administration of the
drug at higher doses. Due to the age limit of 4 years in
the ACZ885D2306 study, no information on very young
children is available so far. Taking into account these
limitations, we suggest that it is reasonable for pediatric
patients above the age of 4 years who have MWS to be
treated with the proposed schedule of 2 mg/kg every 8
weeks. However, patients with the severe CINCA phe-
notype should be more aggressively treated from the
beginning. In our opinion monthly administration of 4
mg/kg should be the starting dose, with a possible pro-
gressive weekly decrease of the dosing frequency accord-
ing to the clinical and laboratory response. Notably, this
schedule has been recently proposed for systemic onset
juvenile arthritis (SoJIA), so far with a satisfactory safety
profile [21].
Further studies of both anakinra and canakinumab in
larger pediatric serial studies are needed, including care-
ful analysis of the pharmacokinetics in children younger
than 4 years of age and long-term follow-up, in order to
achieve a rational approach with IL-1 blockers for the
broad phenotypic spectrum of CAPS in both children
and adults.
Conclusions
The use of canakinumab in daily practice is associated
with persistent satisfactory control of disease activity but
needs progressive dose adjustments in more severely
affected patients. In this respect, the clinical phenotype,
rather than the patient’s age, represents the main vari-
able that determines the indication to start treatment
with more frequent administration of the drug at higher
doses in patients with CINCA.
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